ABSI ABSCI CORP

Absci to Participate in Upcoming Investor Conferences

Absci to Participate in Upcoming Investor Conferences

VANCOUVER, Wash. and NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the following upcoming investor conferences.

  • H.C. Wainwright 2nd Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference

    Fireside chat on Wednesday, April 2 at 10:30 a.m. Eastern Time / 7:30 a.m. Pacific Time
  • 24th Annual Needham Virtual Healthcare Conference

    Fireside chat on Tuesday, April 8 at 3:45 p.m. Eastern Time / 12:45 p.m. Pacific Time

Interested parties may access live and archived webcasts of the fireside chat sessions on the company’s investor relations website at: .

About Absci

is a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our ™ platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed candidates to wet lab-validated candidates in as little as six weeks. Absci’s headquarters is in Vancouver, WA, with our AI Research Lab in New York City and an Innovation Center in Zug, Switzerland. Visit  and follow us on LinkedIn (), X (Twitter) (), and .

Investor Contact

Alex Khan

VP, Finance & Investor Relations

Media Contact



EN
26/03/2025

Underlying

ABSIABSCI CORP

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ABSCI CORP

 PRESS RELEASE
Free
ABSI ABSCI CORP

Absci Reports Business Updates and Fourth Quarter and Full Year 2025 F...

Absci Reports Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results Successfully dosed first three cohorts in SAD portion of ongoing ABS-201™ HEADLINE trial; well-tolerated with favorable emerging safety data Unveiled human ex vivo data demonstrating that ABS-201 stimulates hair growth and regenerates follicle stem cell niche Appointed seasoned biopharmaceutical executive Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer Cash, cash equivalents, and marketable securities sufficient to fund operations into the first half of 2028 VANCOUVER, Wash. an...

March 24, 2026 1 EN
 PRESS RELEASE
Free
ABSI ABSCI CORP

Absci Launches ABS-201 Endometriosis Advisory Board with Leading Exper...

Absci Launches ABS-201 Endometriosis Advisory Board with Leading Experts from Yale, UCSF, Duke, and the Mayo Clinic Experts at the forefront of reproductive medicine, fertility, and translational research will guide the clinical research program for a new therapeutic antibody treatment VANCOUVER, Wash. and NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI,  announced the launch of an endometriosis advisory board for its ABS-201 program in clinical devel...

March 24, 2026 1 EN
 PRESS RELEASE
Free
ABSI ABSCI CORP

Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) VANCOUVER, Wash. and NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced that on March 3, 2026, the company granted a non-statutory stock option to purchase an aggregate of 650,000 shares of its common stock to Dr. Ransi Somaratne in connection with his employment as Absci’s Chief Medical Officer. The inducement grant was previously approved by the Compensation Committee ...

March 6, 2026 1 EN
 PRESS RELEASE
Free
ABSI ABSCI CORP

Absci Strengthens Clinical Leadership with Appointment of Ransi Somara...

Absci Strengthens Clinical Leadership with Appointment of Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer Former Vertex executive to spearhead the clinical development of Absci’s expanding AI-designed therapeutics pipeline Chief Innovation Officer Andreas Busch to retire March 31, 2026 and will continue to co-chair Absci’s Scientific Advisory Board VANCOUVER, Wash. and NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the app...

March 3, 2026 1 EN
 PRESS RELEASE
Free
ABSI ABSCI CORP

Absci to Report Business Updates and Fourth Quarter and Full Year 2025...

Absci to Report Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results on March 24, 2026 VANCOUVER, Wash. and NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will report business updates and financial and operating results for the fourth quarter and full year 2025 after market close on Tuesday, March 24, 2026. Absci management will webcast a corresponding conference call beginning at 4:30 p.m....

February 24, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch